2Sanceau J Y, Labrie F, Gauthier S. Synthesis of ^14C-labelled EM-800 (SCH 57050) and EM-652 · HCI (SCH 57068 · HCl, acolhifene), pure selective estrogen receptor modulators [J]. J Label Comp Radiopharm, 2004, 47 (11) : 741- 752.
3Labrie F, Champagne P, Labrie C, et al. Activity and safety of the antiestrogen EM 800, the orally active precursor of acolbifene, in tamoxifen-resistant breast cancer [J]. J Clin Oncol, 2004, 22(5): 864-871.
4Suprabhat R, Suprabhat S. The potent triarylethylene pharmacophore[J]. Drugs Fur, 2004, 29(2): 185-203.
5Reyderman L, Statkevich P, Cutler D L, et al. Rising multiple dose pharmaeokinetics of acolbifene in combination with estradiol [OL]. [2009-12-10]. http://www. aapsj. org/abstracts/AM-2002/AAPS2002-002345. PDF.
6Roy J, Couillard S, Gutman M, et al. A novel pure SEMR achieves complete regression of the majority of human breast cancer tumors in nude mice [J]. Breast Cancer Res Treat, 2003, 81(3):223-229.
同被引文献7
1Turner C H, Sato M, Bryant H U. Raloxifene preserves bone strength and bone mass in ovariectomized rats [J]. Endocrinology, 1994, 135: 2001-2005.
2Black L J, Sato M, Rowley E R, et al. Raloxifene (LY139481 HCI) prevents bone loss and reduces serum cholesterol without causing uterine hypertrophy in ovariectomized rats [J]. J Clin Invest, 1994, 93: 63-69.
3SorberaLA, Castaner J, Bayes M. Ospemifene [J]. Drug Fut, 2004, 29 (1): 38.
4Morello K C, Wurz G T, DeGregorio M W. Pharmacokinetics of selective estrogen receptor modulators [J]. Clin Pharmacokinet, 2003, 42 (4): 361-372.
5Gennari L, Merlotti D, Valleggi F, et al. Ospemifene use in postmenopausal women [J]. Expert Opin Investigl Drugs, 2009, 18 (6): 839-849.
6Voipio S K, Komi J, Kangas L, et al. Effects ofospemifene ( FC- 1271 a) on uterine endometrium, vaginal maturation index, and hormonal status in healthy postmenopausal women [J]. Maturitas, 2002, 43 (3): 207-214.
7Rutanen E M, Heikkinen J, Halonen K, et al. Effects of ospemifene, a novel SERM, on hormones, genital tract, elimacteriesymptoms, and quality of life in postmenopausal women: a double-blind, randomized trial [J]. Menopause, 2003, 10 (5): 433-439.
